MedTrace Logo

New-onset Diabetes and Left Ventricular Hypertrophy in Renal Transplantation

NCT01976689 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 159

Last updated 2013-11-07

No results posted yet for this study

Summary

New-onset diabetes (NODAT) after solid organ transplantation is an important clinical challenge associated to increased risk of cardiovascular (CV) events. In end-stage renal disease (ESRD) patients, the impact of arterial stiffness on all-cause and CV mortality has been clearly documented. Arterial stiffness has a pivotal role in the genesis of high blood pressure (SBP), increased left ventricular hypertrophy (LVH), and consequently CV mortality. Both LVH and arterial stiffness are independent determinants of CV disease in patients with ESRD. The aim of this study is to evaluate the relationship between post-transplant new-onset diabetes and arterial stiffness and left ventricular mass index (LVMI) in kidney transplant recipients.

Conditions

  • Diabetes Mellitus Nos New Onset
  • Hypertrophy, Left Ventricular
  • Vascular Stiffness

Sponsors & Collaborators

  • Baskent University

    lead OTHER

Principal Investigators

  • Siren Sezer, Prof. Dr. · Baskent University, Department of Nephrology

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-03-31
Completion
2013-09-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01976689 on ClinicalTrials.gov